| Title |
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
|
|---|---|
| Published in |
Tumor Biology, January 2012
|
| DOI | 10.1007/s13277-012-0316-4 |
| Pubmed ID | |
| Authors |
Guus A. M. S. van Dongen, Alex J. Poot, Danielle J. Vugts |
| Abstract |
During the last decade, the discovery of critical tumor targets has boosted the design of targeted therapeutic agents with monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) receiving most of the attention. Immuno-positron emission tomography (immuno-PET) and TKI-PET, the in vivo tracking and quantification of mAbs and TKIs biodistribution with PET, are exciting novel options for better understanding of the in vivo behavior and efficacy of these targeted drugs in individual patients and for more efficient drug development. Very recently, current good manufacturing practice compliant procedures for labeling of mAbs with positron emitters have been described, as well as the preparation of some radiolabeled TKIs, while the first proof of principle studies has been performed in patients. In this review, technical developments in immuno-PET and TKI-PET are described, and their clinical potential is discussed. An overview is provided for the most appealing preclinical immuno-PET and TKI-PET studies, as well as the first clinical achievements with these emerging technologies. |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 94 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 22 | 23% |
| Researcher | 22 | 23% |
| Student > Master | 9 | 9% |
| Student > Bachelor | 7 | 7% |
| Student > Postgraduate | 6 | 6% |
| Other | 8 | 8% |
| Unknown | 22 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 22% |
| Chemistry | 18 | 19% |
| Agricultural and Biological Sciences | 11 | 11% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 14 | 15% |
| Unknown | 26 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 July 2022.
All research outputs
#7,485,894
of 22,880,230 outputs
Outputs from Tumor Biology
#412
of 2,623 outputs
Outputs of similar age
#71,927
of 246,844 outputs
Outputs of similar age from Tumor Biology
#9
of 18 outputs
Altmetric has tracked 22,880,230 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,623 research outputs from this source. They receive a mean Attention Score of 2.3. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 246,844 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.